A Design-Conversed Strategy Establishes the Performance Safe Space for Doxorubicin Nanosimilars.

ACS Nano · 2024 · PMC10906076 · PMID 38359902

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an expected trendno p-value reported

18 The deconvoluted plasma profiles reflect an expected trend for the slow-releasing and long-circulating liposomal formulation (refer to Supporting Information , Figure S1).

also in 167 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.